Track topics on Twitter Track topics that are important to you
SummaryKey Content of Chapters Including and can be customizedPart 1:Market Overview, Development, and Segment by Type, Application RegionPart 2:Global Market by company, Type, Application RegionPart 3:North America Market by company, Type, Application RegionPart 46:Key Regions of North America Market by Type, ApplicationPart 7:Company information, Sales, Cost, Margin etc.Part 8:ConclusionMarke...
Japan has approved a drug that its maker says can kill the flu virus in 24 hours, advancing what health experts believe could be a breakthrough in the way the illness is treated. Friday's fast-tracked approval from Japan's health ministry means Shionogi & Co.
When Teva Pharmaceuticals announced recently that it would begin selling a copycat version of Syprine - an expensive drug invented in the 1960s - the news seemed like a welcome development for people taking old drugs that have skyrocketed in price. Syprine, which treats a rare condition known as Wilson disease, gained notoriety after Valeant Pharmaceuticals International raised the price of the dr...
The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended approval of olaparib tablets (Lynparza) as a maintenance therapy for patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.
The European Medicines Agency's Committee for Medicinal Products for Human Use has recommended approval of denosumab (Xgeva) for the prevention of skeletal-related events in patients with multiple myeloma.
Novo Nordisk has positive Phase III trial results for its oral version of semaglutide, a GLP-1 based treatment for type II diabetes. This could be the first oral GLP-1 treatment on the market, making it easier for patients to take ... This awesome article Novo Nordisk Gets Close to Launching the First Oral GLP-1 Drug for Diabetes appeared first on Labiotech.eu. Be kind and don't copy it without as...
Leonard Gomella, MD, shares his insight on the recent FDA approvals and other ongoing progress in the treatment of patients with prostate cancer.
Five medicines recommended for approval, including two orphans
Edison Investment Research - Pharmaceutical & healthcare - MagForce: MagForce has received IDE approval to start its first pivotal clinical trial evaluating NanoTherm focal ablation therapy for prostate cancer in the US. This is a major milestone for the company. Prostate cancer in the US presents a significant market opportunity (representing ~60% of our rNPV) and makes sense strategically as a f...
The pan-Canadian Pharmaceutical Alliance (pCPA) announced on 29 January 2018 that together with participating federal, provincial and territorial public drug plans, and the Canadian Generic Pharmaceutical Association (CGPA), they are launching a new five-year generics initiative. As a part of this, Canada’s generic drugs industry has agreed to reduce prices of generics in exchange for the r...
Further follow-up of AMD patients treated with Apellis' drug appeared to support earlier Phase 2 results.
The U.S. Food and Drug Administration (FDA) is advising caution before prescribing the antibiotic clarithromycin (Biaxin) to patients with heart disease because of a potential increased risk of heart problems or death that can occur years later. Our recommendation is based on our review of the results of a 10-year follow-up study1 of patients with coronary heart disease from a large clinical tri...
MabSpace Biosciences announces on February 16th, 2018 FDA cleared Investigational New Drug (IND) for MSB2311, a humanized programmed death protein-ligand 1 (PD-L1) antibody for the treatment of patients with locally advanced/metastatic solid tumors. MabSpace plans to start a first-in-human, open label, multiple center, dose escalation and dose expansion st...
NewsScientists in Germany who developed a new way to make a key malaria drug several years ago said Wednesday they have come up with a technique to make the process even more efficient, which should increase global access and reduce the cost.
One of GW Pharma’s cannabinoid drugs for epilepsy has suffered a set back in a Phase IIa trial as a placebo matched its capacity to reduce the frequency of focal seizures. GW Pharma wants to use cannabinoid drugs to treat conditions like autism ... This awesome article GW Pharma’s Latest Cannabinoid Drug Pegged Back by a Placebo in Phase II appeared first on Labiotech.eu. Be kind an...
Biohaven is to use Catalent's fast-dissolving technology for rapid delivery of its migraine drug.
PRINCETON, NJ--(Marketwired - February 22, 2018) - Adgero Biopharmaceuticals Holdings, Inc. ("Adgero" or the "Company"), a privately-held biopharmaceutical company leveraging its late stage photodynamic therapy ("PDT") platform for the treatment of serious cutaneous oncology indications, announced today that the U.S. Food and Drug Administration ("FDA") has granted Orphan Drug Designation to REM-0...
In an already competitive diabetes market, Novo Nordisk may have gained a significant edge with the results of its Phase III trial of GLP-1 drug Ozempic (semaglutide).
The speedy trial design means the first of Vertex’s three-drug regimens for cystic fibrosis could have top-line results by the end of this year or early in 2019 — faster…
The CHMP has communicated a positive trend vote for the rucaparib MAA under review for the treatment of women with advanced BRCA-mutant ovarian cancer and expects to vote on the treatment indication at their scheduled meeting in March 2018 Pending a positive recommendation by CHMP, final approval by the European Commission w...
CHI’s Discovery on Target, Sheraton Boston, Sept. 25-28, 2018 Reporter: Aviva Lev-Ari, PhD, RN ANNOUNCEMENT Leaders in Pharmaceutical Business Intelligence (LPBI) Group is a selected CHI Business Partner for Media Communication for this event as well a provider of REAL TIME PRESS COVERAGE for this cardinal event in the domain of Drug Discovery and Drug Delivery. Dr. Aviva [̷...
NewsThe partnership will use Emulate's lab-ready Human Emulation System comprised of Organ-Chips, instrumentation, and software apps to discover and develop new classes of therapeutic antibodies and drug combinations.
NewsEmulate, Inc. announces strategic partnership with leading pharmaceutical company to apply the ‘Human Emulation System’ as a platform for drug discovery.
NewsFDA's tentative approval of Mylan's NDA for dolutegravir, emtricitabine, and tenofovir alafenamide tablets was issued under the President's Emergency Plan for AIDS Relief (PEPFAR). The antiretroviral will be immediately available in developing countries.
NewsUnder the deal, Ionis receives a $30 million license fee and may also receive up to $300 million in additional payments. AstraZeneca will be responsible for developing and commercializing the drug to treat a genetically associated form of kidney disease.